Effect of Different Doses of Thalidomide in Experimentally Induced Inflammatory Bowel Disease in Rats

Abstract

The present study was carried out to evaluate the effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. Adult Wistar rats of either sex were used (n = 36). Colitis was induced by a single intra-colonic application of 20 mg 2,4,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 35% ethanol into the descending colon. Rats were divided into six groups (n = 6). Animals were treated with vehicle (ethanol), TNBS dissolved in 35% ethanol, thalidomide (with different doses of 50, 100 and 150 mg/kg body weight), and sulfasalazine (360 mg/kg body weight) for 14 days. After completion of 14 days of treatment, animals were killed and the following parameters were assessed: morphological score, histological score and biochemical parameters (myeloperoxidase, malondialdehyde and tumour necrosis factor-α ). Results showed thalidomide with different doses provided protection against TNBS-induced colonic damage. There was significant protection with thalidomide 150 mg/kg body weight compared to controls (P < 0.001). All the biochemical parameters were highly reduced in the entire thalidomide-treated group compared to controls particularly with thalidomide 150 mg/kg body weight (P < 0.001). Treatment with thalidomide restored malondialdehyde as well as reduction of myeloperoxidase and tumour necrosis factor-α towards normal levels. Morphological and histological score were significantly reduced in all the treated groups with significant effect found with 150 mg/kg (P < 0.001). Our results indicate efficacy of thalidomide in TNBS induce experimental colitis model in rats but present findings requires further investigation to establish the real safety and efficacy in human beings.

Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis

“…In present study, treatment with endostatin in a dose which had anti-angiogenic and anti-tumor effects in vivo (Folkman, 2006) significantly improved clinical and histologic signs of DSS-induced UC in MMP-9 KO mice. These results are supported by other studies showing that the potent inhibitor of angiogenesis thalidomide attenuates IBD in patients (Plamondon et al, 2007;Vasiliauskas et al, 1999) and in animal models (Prakash et al, 2008). Furthermore, deletion of thrombospondin-1 in mice, which is upregulated by endostatin (Abdollahi et al, 2004), evoked more severe experimental UC vs. WT mice (Punekar et al, 2008).…”

Evidence for the contribution of tumour necrosis factor in oedema formation induced by histamine in the hind paw of the rat

“…Both drugs have been shown to be biologically effective in rats, in conditions associated with overexpression of TNF [12,13]. In order to compare the effect of TNF blockage to that of H 1 R antagonism, we also examined the effect of loratadine, a classic second generation antihistamine.…”

Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats

“…5-ASA can reduce neutrophil infiltration and formation of reactive oxygen metabolites by neutrophils [42]. Prakash et al [43] showed significant reduction of the neutrophil infiltration and mucosal inflammation after treatment of rat model of crohn's disease with salfasalazine. Lim and Hanauer [41] recorded that sulfasalazine induced significant remission compared to placebo in patients with Crohn's disease.…”